Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 832

1.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

2.

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.

Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S.

Immunology. 2007 Jul;121(3):392-404. Epub 2007 Mar 26.

3.

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.

4.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.

5.

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.

Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE.

Blood. 2009 Apr 16;113(16):3735-43. doi: 10.1182/blood-2008-10-182048. Epub 2008 Dec 24.

6.

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.

Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM.

J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7.

7.

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.

Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR.

Mol Cancer Ther. 2008 Aug;7(8):2517-27. doi: 10.1158/1535-7163.MCT-08-0201.

8.

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.

Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.

9.

CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, Inzunza HD, Li H, Thomas S, Johnson S, Stavenhagen J, Koenig S, Bonvini E.

Blood. 2006 Oct 1;108(7):2384-91. Epub 2006 Jun 6.

10.

Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.

Imai M, Ohta R, Varela JC, Song H, Tomlinson S.

Cancer Res. 2007 Oct 1;67(19):9535-41.

11.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Clynes RA, Towers TL, Presta LG, Ravetch JV.

Nat Med. 2000 Apr;6(4):443-6.

PMID:
10742152
12.

Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.

Heijnen IA, Glennie MJ, van de Winkel JG.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):166-70.

PMID:
9435865
13.

Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y.

Mol Immunol. 2008 May;45(10):2752-63. doi: 10.1016/j.molimm.2008.02.003. Epub 2008 Mar 18.

PMID:
18353438
14.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

15.

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.

Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.

J Immunother. 2007 Jan;30(1):64-74.

PMID:
17198084
16.

Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice.

Santiago-Raber ML, Amano H, Amano E, Baudino L, Otani M, Lin Q, Nimmerjahn F, Verbeek JS, Ravetch JV, Takasaki Y, Hirose S, Izui S.

Arthritis Rheum. 2009 Aug;60(8):2408-17. doi: 10.1002/art.24787.

17.

[Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].

Hamaguchi Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Feb;32(1):29-34. Review. Japanese.

18.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.

19.

Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.

Kumpel BM, Beliard R, Brossard Y, Edelman L, de Haas M, Jackson DJ, Kooyman P, Ligthart PC, Monchâtre E, Overbeeke MA, Puillandre P, de Romeuf C, Wilkes AM.

Transfus Clin Biol. 2002 Jan;9(1):45-53.

PMID:
11889899
20.

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.

J Mol Biol. 2010 Jun 11;399(3):436-49. doi: 10.1016/j.jmb.2010.04.001. Epub 2010 Apr 9.

PMID:
20382161

Supplemental Content

Support Center